Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixazomib + dexamethasone vs physician’s choice in relapsed or refractory systemic AL amyloidosis
jRCT2080223632Phase 3Completed
- Sponsor
- Takeda
- Start
- Aug 2017
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of ixazomib in light-chain amyloidosis (2 arms), sponsored by Takeda. Primary endpoint: Primary Outcome Measure. Started Aug 2017; status: completed.
02
Drugs
ixazomib
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on jRCT2080223632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223632.